# Atomwise

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atomwise

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.atomwise.com
- Total disclosed funding: $219M
- Latest round: Series C (Mar 1, 2024)
- Investors on record: 12

## About

Atomwise, Inc. is a U.S.-based company focused on advancing drug discovery using artificial intelligence, aiming to enhance the efficiency of developing small molecule medicines through its innovative machine learning technologies.Founded in 2012 and headquartered in San Francisco, US, Atomwise, Inc. specializes in leveraging AI for drug discovery. The company has not undergone any significant operational pivots and does not have known parent or subsidiary companies. The founding team includes Abraham Heifets and Izhar Wallach, with Heifets serving as CEO. Atomwise has successfully completed 8 deals, with its latest funding round, Series C, raising USD 45.00 mn on March 1, 2024, bringing the total amount raised to USD 45.00 mn and the current company valuation to USD 231.00 mn.Atomwise harnesses artificial intelligence to improve drug discovery, primarily through its proprietary machine learning-based discovery engine. This technology utilizes convolutional neural networks and extensive chemical libraries to identify and develop small molecule medicines. Atomwise's product offerings include both wholly owned and co-developed assets, addressing critical healthcare challenges related to drug efficacy and safety. The company serves a diverse global client base, including pharmaceutical companies, biotechnology firms, and research institutions in markets across North America, Europe, and Asia, while focusing on streamlining the drug discovery process to minimize time and costs in bringing new pharmaceuticals to market.Atomwise generates revenue through B2B partnerships and collaborations with pharmaceutical and biotechnology companies. Its business model includes licensing its AI technology and providing tailored drug discovery services, which may also involve milestone payments and royalties tied to the success of compounds developed. The specifics of their pricing plans are not publicly disclosed, yet the company is positioned as a strategic partner in the competitive pharmaceutical sector, with client investments leading to advancements in drug development outcomes.In March 2024, Atomwise, Inc. raised USD 45.00 mn in Series C funding, co-led by Khosla Ventures and B Capital Group. This funding will be utilized to support the development of new AI-driven drug discovery products and expand into emerging markets, targeting regions such as Asia and Europe within the next few years.

## Funding rounds

- Series C, Mar 1, 2024, $45M — Khosla Ventures, B Capital
- Series B, Jun 10, 2020, $123M — Tencent Investment, Y Combinator, DCVC, AME Cloud Ventures, Dolby Family Ventures, B Capital, Baidu Ventures, Sanabil Investments
- Series A, Feb 1, 2018, $45M — Khosla Ventures, Tencent Investment, Y Combinator, DCVC, Dolby Family Ventures, DFJ Growth, Monsanto Growth Ventures, B Capital, Baidu Ventures
- Seed, Jun 3, 2015, $6M — Khosla Ventures, DCVC, AME Cloud Ventures, DFJ Growth, Awaken Capital
- Seed, Mar 25, 2015, $0.1M — Y Combinator

## Investors

- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed, Series A, Series B
- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Seed, Series A, Series C
- DCVC (https://capitalatlas.ai/funds/dcvc) — Seed, Series A, Series B
- AME Cloud Ventures (https://capitalatlas.ai/funds/ame-cloud-ventures) — Seed, Series B
- DFJ Growth (https://capitalatlas.ai/funds/dfj-growth) — Seed, Series A
- Awaken Capital (https://capitalatlas.ai/funds/awaken-capital) — Seed
- Tencent Investment — Series A, Series B
- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Series A, Series B
- Monsanto Growth Ventures (https://capitalatlas.ai/funds/monsanto-growth-ventures) — Series A
- B Capital (https://capitalatlas.ai/funds/b-capital) — Series A, Series B, Series C
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series A, Series B
- Sanabil Investments (https://capitalatlas.ai/funds/sanabil-investments) — Series B